Sandbox: sadaf: Difference between revisions
Jump to navigation
Jump to search
Line 49: | Line 49: | ||
|- | |- | ||
! rowspan="23" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection | ! rowspan="23" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection | ||
! align="center" style="background:#DCDCDC;" + | | ! align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia | ||
! | ! | ||
| | | | ||
Line 73: | Line 73: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | ! align="center" style="background:#DCDCDC;" + |Chronic liver disease | ||
! | ! | ||
| | | | ||
Line 97: | Line 97: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!portal hypertension | ! align="center" style="background:#DCDCDC;" + |portal hypertension | ||
! | ! | ||
| | | | ||
Line 121: | Line 121: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | ! align="center" style="background:#DCDCDC;" + |Hypersplenism | ||
! | ! | ||
| | | | ||
Line 145: | Line 145: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | ! align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia | ||
! | ! | ||
|Antibody-mediated platelet destruction | |Antibody-mediated platelet destruction | ||
Line 169: | Line 169: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="7" | | ! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders | ||
!MYH-9 related disorders | ! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 193: | Line 193: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Bernard-Soulier syndrome | ! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 216: | Line 216: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Gray platelet syndrome | ! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 239: | Line 239: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Wiskott-Aldrich syndrome | ! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 262: | Line 262: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Thrombocytopenia with absent radius (TAR) syndrome | ! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 285: | Line 285: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Alport syndrome | ! align="center" style="background:#DCDCDC;" + |Alport syndrome | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 308: | Line 308: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Von Willebrand disease | ! align="center" style="background:#DCDCDC;" + |Von Willebrand disease | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 427: | Line 427: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="2" align="center" style="background:#DCDCDC;" + | | ! rowspan="2" align="center" style="background:#DCDCDC;" + |Viral infections | ||
!rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus | ! align="center" style="background:#DCDCDC;" + |rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 452: | Line 452: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | ! align="center" style="background:#DCDCDC;" + |HIV | ||
! | ! | ||
* Direct toxicity to megakaryocytes | * Direct toxicity to megakaryocytes | ||
Line 478: | Line 478: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="3" |Bacterial infections | ! rowspan="3" align="center" style="background:#DCDCDC;" + |Bacterial infections | ||
! | ! align="center" style="background:#DCDCDC;" + |Sepsis | ||
!Direct bone marrow suppression | !Direct bone marrow suppression | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 502: | Line 502: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Helicobacter pylori | ! align="center" style="background:#DCDCDC;" + |Helicobacter pylori | ||
!Immune thrombocytopenia | !Immune thrombocytopenia | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 525: | Line 525: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | ! align="center" style="background:#DCDCDC;" + |Leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 548: | Line 548: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="2" | | ! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites | ||
!Malaria | ! align="center" style="background:#DCDCDC;" + |Malaria | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 572: | Line 572: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Babesiosis | ! align="center" style="background:#DCDCDC;" + |Babesiosis | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 596: | Line 596: | ||
|- | |- | ||
! rowspan="6" |Medications/toxicity | ! rowspan="6" |Medications/toxicity | ||
! | ! align="center" style="background:#DCDCDC;" + |Drug-induced immune thrombocytopenia | ||
! | ! | ||
* Antibiotics | * Antibiotics |
Revision as of 03:12, 13 August 2018
Thrombocytopenia Differential Diagnosis
Differentiating the diseases that can cause thrombocytopenia:
Category | Condition | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Signs | ||||||||||||||||||||||
Lab Findings | Imaging | ||||||||||||||||||||||
Severity | Fever | Bleeding | BP | Other | CBC | PBS | Coagulopathy | ||||||||||||||||
Mechanism | |||||||||||||||||||||||
Infection | Gestational thrombocytopenia | ||||||||||||||||||||||
Chronic liver disease | |||||||||||||||||||||||
portal hypertension | |||||||||||||||||||||||
Hypersplenism | |||||||||||||||||||||||
Immune thrombocytopenia | Antibody-mediated platelet destruction | Moderate to severe | - | Diagnosis of exclusion | |||||||||||||||||||
Congenital platelet disorders | MYH-9 related disorders | ||||||||||||||||||||||
Bernard-Soulier syndrome | |||||||||||||||||||||||
Gray platelet syndrome | |||||||||||||||||||||||
Wiskott-Aldrich syndrome | |||||||||||||||||||||||
Thrombocytopenia with absent radius (TAR) syndrome | |||||||||||||||||||||||
Alport syndrome | |||||||||||||||||||||||
Von Willebrand disease | |||||||||||||||||||||||
Viral infections | rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus | ||||||||||||||||||||||
HIV |
|
||||||||||||||||||||||
Bacterial infections | Sepsis | Direct bone marrow suppression | |||||||||||||||||||||
Helicobacter pylori | Immune thrombocytopenia | ||||||||||||||||||||||
Leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections | |||||||||||||||||||||||
Intracellular parasites | Malaria | ||||||||||||||||||||||
Babesiosis | |||||||||||||||||||||||
Medications/toxicity | Drug-induced immune thrombocytopenia |
|
Occurrence of drug-dependent, platelet-reactive antibodies | ||||||||||||||||||||
Heparin-induced thrombocytopenia | |||||||||||||||||||||||
Cytotoxic chemotherapy | |||||||||||||||||||||||
Radiation therapy | Predictable, dose-dependent myelosuppression | ||||||||||||||||||||||
OTC agents | Quinine-containing beverages | ||||||||||||||||||||||
Alcohol | |||||||||||||||||||||||
Malignancy | |||||||||||||||||||||||
Nutrient deficiencies | folate, vitamin B12, copper | an autoimmune mechanism | Mild | ||||||||||||||||||||
Thrombotic microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP) | ||||||||||||||||||||||
Hemolytic uremic syndrome (HUS) | |||||||||||||||||||||||
Drug-induced TMA (DITMA) | |||||||||||||||||||||||
Bone marrow disorders | Myelodysplastic syndromes | ||||||||||||||||||||||
Aplastic anemia | |||||||||||||||||||||||
Acute leukemia | |||||||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria (PNH) | |||||||||||||||||||||||
Rheumatologic/autoimmune disorders | Systemic lupus erythematosus (SLE) | ||||||||||||||||||||||
Antiphospholipid syndrome (APS) | autoantibody-mediated syndrome | ||||||||||||||||||||||
Felty's syndrome | splenomegaly | ||||||||||||||||||||||
vascular | giant capillary hemangioma, | platelet destruction | |||||||||||||||||||||
large aortic aneurysms, | platelet destruction | ||||||||||||||||||||||
cardiopulmonary bypass | platelet destruction | ||||||||||||||||||||||
Post-transfusion purpura | immune-mediated platelet destruction |